New data support advancement of the Phase 3 PALM-PAH trial, a randomized, double-blind, placebo-controlled study now enrolling, with change in 6MWD as its primary endpoint.
Daily Inhaled TPIP Improved PAH Measures at 12 Months in OLE
New data support advancement of the Phase 3 PALM-PAH trial, a randomized, double-blind, placebo-controlled study now enrolling, with change in 6MWD as its primary endpoint.